Cite

HARVARD Citation

    Arribas, A. et al. (n.d.). DEVELOPMENT OF NOVEL PRECLINICAL MODELS OF SECONDARY RESISTANCE TO THE PI3KΔ INHIBITOR IDELALISIB IN SPLENIC MARGINAL ZONE LYMPHOMA (SMZL). Hematological oncology. p. 254. [Online]. 
  
Back to record